NEW YORK (GenomeWeb News) - Navigenics said this week that it has formed its board of directors and advisory boards.
The board of directors includes David Agus, a company cofounder; Mari Baker, Navigenics’ president and CEO; David Brailer, chairman of Health Evolution Partners; John Doerr, a partner of Kleiner Perkins Caufield and Byers; Dana Mead, also a partner of Kleiner Perkins Caufield and Byers; and Sue Siegel, a partner of Mohr Davidow Ventures.
Agus also chairs the company’s clinical advisory board. He is the research director of the Louis Warschaw Prostate Cancer Center and director of the Spielberg Family Center for Applied Proteomics at Cedars-Sinai Medical Center.
Additional members of the clinical advisory board are Carlos Camargo, an emeritus clinical professor of medicine at Stanford University; Daniel Federman, a professor of medicine at Harvard Medical School; Bruce Landon, an associate professor of healthcare at Harvard Medical School and associate professor of medicine at Beth Israel Deaconess Medical Center; Redonda Miller, an associate professor of medicine at Johns Hopkins University; and Michael Nierenberg, medical director of Navigenics and emeritus clinical professor of medicine at Stanford University.
Jeffrey Trent, president and scientific director of the Translational Genomics Research Institute in Arizona, chairs Navigenics’ scientific advisory board. Other SAB members are David Botstein, professor of genomics at Princeton University; Isaac Kohane, professor of pediatrics and health sciences as well as health sciences and technology at Harvard Medical School; Nicholas Schork, director of research at Scripps Genomic Medicine and professor of molecular and experimental medicine at the Scripps Research Institute; Dietrich Stephan, cofounder and chief science officer of Navigenics and deputy director for discovery research at TGen.
Peggy Conrad is the chair of Navigenics’ genetic counseling task force. She is a practicing genetic counselor with more than 10 years' experience in hereditary cancer genetics. Additional members of the task force are Elissa Levin, genetics counseling program director at Navigenics; and Kelly Ormond, associate professor of genetics and director of the human genetics and genetic counseling graduate training program at Stanford.
Greg Simon chairs the policy and ethics task force. He is the president of FasterCures-The Center for Accelerating Medical Solutions. Other members of that task force are Rachel Grob, associate dean of graduate studies and director of the Child Development Institute at Sarah Lawrence College; Kathi Hanna, an analyst, writer, and editor specializing in biomedical research policy and previously research director and editorial consultant to President Clinton's National Bioethics Advisory Commission; and Paul Slovic, founder and president of Decision Research.
Ronald Lowy has joined the board of directors of Helicos BioSciences, the company said this week. He is the former president and CEO of Fisher Biosciences, a division of Fisher Scientific (now Thermo Fisher Scientific). Prior to that, he was president of global connectivity solutions for ADC Telecommunications. He also served as president and chief operating officer at Krone.
BioSeek said this week it has named Michael Venuti as CEO and a member of the board of directors. Venuti will take over the top spot vacated by Peter Staple, who will remain as an investor and board member.
Venuti formerly was CEO of Discovery Partners International.
Steven Samuelsson has taken the post of director of imaging in SRI International’s Biosciences Division. In the role, Samuelsson will run the microscopy and imaging-based assay efforts for drug development and discovery. He formerly was associate director of experimental pathology at Eyetech Pharmaceuticals.
Keygene has named Wim-Jan Koot to be manager of intellectual property and IP commercialization. Koot comes to Keygene from Organon, where he was senior director of global research alliances.
The BioIndustry Association said this week it has appointed Clive Dix to succeed Simon Best as chairman. Dix spent 15 years at pharmaceutical companies, and he currently is non-executive chairman of Modern Biosciences and was a co-founder of PowderMed.
NextGen Sciences has tapped Mike Pisano to be CEO. Pisano comes to Nextgen from Proteomic Research Services, which NextGen acquired in November 2006, where he was cofounder and CEO.
Pisano formerly was head of protein production at Rhone-Poulenc Rorer Pharmaceuticals and was at Aventis Pharmaceuticals and VP of proteomic R&D at Genomic Solutions.
Julie Stenken has been named as the Twenty-First Century Chair in Proteomics at the University of Arkansas. Stenken studies proteins that control immune system responses to foreign plants and peptides involved in drug addiction.
BioTrove has named Jeffrey Leathe as CFO and has charged him with overseeing IT infrastructure development. Leathe has experience in both large public companies and in start-ups, BioTrove said. He formerly was at Apogent, Prime Computer, and at Congoleum Industries. He also is director and chairman of the audit committee for Bottomline Technologies and is a director of the Senator George J. Mitchell Research Scholarship Institute.
Former Biotechnology Industry Organization director of government relations Barrett Thornhill has joined the law firm of Foley Hoag LLP as a health policy specialist in its Washington, DC, office. Before handling legislative efforts at BIO, Thornhill was a health policy legislative assistant for Senator Mike Crapo and worked with other US representatives.
SRU Biosystems has appointed Richard Wagner to be company president and CEO and member of the board of directors. Wagner is replacing Owen Dempsey, who left the company to “pursue other interests,” the company said.
Wagner has 18 years experience developing drug and diagnostic screening products and processes. He was involved in starting Phylos, where he invented antibody technologies and secured Series B financing, and he was in cell biology at Gilead Sciences.
Graham Mullis will take over the CEO position at Lab21 after serving as an executive at 1-800 Contacts and Biocompatibles International. Healso served in pharmaceutical roles at Hoechst Roussel and at RP Scherer, and he most recently worked at Optivue.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.